-Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced dosing of the first pati...
California’s Desert Oasis Healthcare (DOHC) implements Rimidi’s Respiratory Module for respiratory patient monitoring, based on data collecte...
Addressing a long-term shortcoming in DNA evidence for rape and sexual assault cases, New Orleans-based InnoGenomics has developed a nanotech method, Sperm...
Curia, a leading contract research, development and manufacturing organization, today announced a collaboration with Corning Incorporated to expand and acc...
Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian Healthtech company, announce...
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced it h...
Harm Reduction Therapeutics, a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths by making low-cost naloxone a...
"There are many reasons parents elect to enroll children in clinical trials including access to vaccines that are not yet available to the general public, ...
"The FDA's accelerated approval program has provided patients with cancer earlier access to novel treatments that can be practice changing," said Richard P...
Orion Health, a global leader in population health software, is strengthening its position in North America with new technology and the appointment of Jame...
GENETWORx is a clinical diagnostics laboratory based outside of Richmond, VA, that specializes in molecular pathogen and pharmacogenomic testing. GEN...
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) tablets, which ...
Lunit signed a software license agreement with the Hospital Israelita Albert Einstein, Latin America's top medical institution, to provide its AI-based c...
The warrants were offered and sold at the rate of one warrant for every two shares of common stock purchased in the offering, with each full warrant having...
© 2025 Biopharma Boardroom. All Rights Reserved.
